DM
DMAA.US Drugs Made In America Acquisition Corp. Ordinary Shares
- Market cap
- USD 265M
- P/E
- 60.6x
- P/B
- 1.92x
- ROE
- 5.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is DMAA.US undervalued?
Graham numberDMAA.US trades 127.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Drugs Made In America Acquisition Corp. Ordinary Shares fundamental analysis
No fundamental analysis for Drugs Made In America Acquisition Corp. Ordinary Shares yet.
Drugs Made In America Acquisition Corp. Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Full company profileDrugs Made In America Acquisition Corp. Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Drugs Made In America Acquisition Corp. Ordinary Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | - | 0.00 | 0.00 |
| Operating Income | -479.00 | -2.82M | -560K |
| EBITDA | 479K | -2.82M | -560K |
| Net Income | -479.00 | 5.94M | 7.39M |
| EPS | 0.00 | 0.28 | 0.37 |
| Balance Sheet | |||
| Total Assets | 550.82 | 240M | 147M |
| Total Liabilities | 795.67 | 7.28M | 9.14M |
| Shareholders' Equity | -244.00 | 233M | 138M |
| Cash & Short-term Investments | 1.35K | 6.14K | 20.3K |
| Total Debt | 662.32 | - | 950K |
| Cash Flow | |||
| Operating Cash Flow | -172K | -539K | -672K |
| Capital Expenditure | 5.00 | 0.00 | 6.00 |
| Free Cash Flow | -295.00 | -539K | -672K |
| Ratios | |||
| ROE | - | 2.6% | 5.4% |
| ROA | -87.0% | 2.5% | 5.0% |
| Debt to Equity | - | - | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Drugs Made In America Acquisition Corp. Ordinary Shares dividends
Drugs Made In America Acquisition Corp. Ordinary Shares has not paid dividends in the last 2 fiscal years.
Who owns Drugs Made In America Acquisition Corp. Ordinary Shares
- Insiders 23.57%
- Institutions 63.14%
- Public & others 13.30%
- Shares outstanding 24.3M
- Free float 19.8M
Top funds holding DMAA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| First Trust Merger Arbitrage Cl I | 675K | 2.78% | -64.99% | Jun 2026 |
| The Merger Fund A | 565K | 2.33% | -65.30% | Jun 2026 |
| RiverPark Short Term High Yield Instl | 265K | 1.09% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 60.4K | 0.25% | -3.04% | Aug 2026 |
| JNL Multi-Manager Alternative A | 10.3K | 0.04% | 0.00% | Sep 2026 |
| Virtus Westchester Credit Event Fd I | 6.71K | 0.03% | -59.00% | Jun 2026 |
Top institutions holding DMAA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Mizuho Securities USA Inc | 4.07M | 16.76% | +103.48% | Jun 2026 |
| Karpus Management Inc | 2.51M | 10.33% | -0.90% | Jun 2026 |
| Polar Asset Management Partners | 1.15M | 4.72% | -28.38% | Jun 2026 |
| Glazer Capital, LLC | 1,000K | 4.12% | -40.43% | Jun 2026 |
| Wolverine Asset Management LLC | 832K | 3.43% | -46.44% | Jun 2026 |
| Highbridge Capital Management, LLC | 809K | 3.33% | -38.86% | Jun 2026 |
| First Trust Capital Management L.P. | 786K | 3.24% | -64.93% | Jun 2026 |
| Heights Capital Management Inc | 648K | 2.67% | -0.29% | Jun 2026 |
| Westchester Capital Management LLC | 582K | 2.40% | -65.14% | Jun 2026 |
| Clear Street Group Inc | 382K | 1.58% | +8.02% | Jun 2026 |
| Aristeia Capital, LLC | 350K | 1.44% | -60.30% | Jun 2026 |
| SONA ASSET MANAGEMENT (US) LLC | 163K | 0.67% | 0.00% | Jun 2026 |
| RLH Capital LLC | 116K | 0.48% | -63.48% | Jun 2026 |
| Logan Stone Capital, LLC | 110K | 0.45% | 0.00% | Jun 2026 |
| The Toronto-Dominion Bank | 100K | 0.41% | -50.94% | Jun 2026 |
| Meteora Capital, LLC | 97.8K | 0.40% | -74.27% | Jun 2026 |
| Quarry LP | 65.6K | 0.27% | -75.41% | Jun 2026 |
| Geode Capital Management, LLC | 62.3K | 0.26% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 49.9K | 0.21% | +0.02% | Jun 2026 |
| Oakmont Partners, LLC | 36.4K | 0.15% | 0.00% | Jun 2026 |
Drugs Made In America Acquisition Corp. Ordinary Shares company profile
- Company name
- Drugs Made In America Acquisition Corp. Ordinary Shares
- Ticker
- DMAA.US
- ISIN
- KYG2847J1040
- Exchange
- USA Stocks
- Listed since
- Feb 25, 2025
- Sector
- Financial Services
- Industry
- Capital Markets
- Fiscal year end
- December
- Address
- 420 Lexington Avenue, New York, NY, United States, 10170
- Phone
- 646 726 7074
- Website
- dmaacorp.com
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Drugs Made In America Acquisition Corp. Ordinary Shares management
2- Mr. Roger BendelacChief Executive Officer · born 1957
- Mr. Saleem Elmasri CPACFO & Principal Accounting Officer · born 1986